EGFR and prostate cancer: The 11 pathways that are commonly detected in all four approaches are acute myeloid leukemia, chemokine signaling pathway, chronic myeloid leukemia, ErbB signaling pathway, glioma, insulin signaling pathway, neurotrophin signaling pathway, nonsmall cell lung cancer, pancreatic cancer, prostate cancer, type II diabetes mellitus.